Immuneering-logo (1).png
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
12 mars 2024 08h00 HE | Immuneering Corporation
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Immuneering-logo (1).png
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04 mars 2024 08h00 HE | Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...